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Abstract
Background and aim: High-risk pulmonary embolism (PE) represents an important health 
problem in emergency cardiology, being associated with a high rate of mortality. The aim of 
this study is to assess the efficacy and safety of pulmonary intra-arterial thrombolysis with 
streptokinase compared to systemic thrombolysis.
Methods and Results: In our study, 28 patients with acute high risk PE were treated by 
intra-arterial thrombolysis with clinical success rate of 96.4%, while in the group with sys-
temic thrombolysis (24 patients) the rate of clinical success was significantly lower (70.8%). 
Also, pressure gradient between right ventricle (RV) and right atrial (RA) (PRV-RA) decreased 
significantly in patients treated by pulmonary intra-arterial thrombolysis instead of systemic 
thrombolysis. Mortality during the hospitalization was 0% in the group with local thrombolysis 
and 29.2% in the other group, with a significant statistical difference. Major bleeding com-
plications appeared in 14.3% of the patients with local thrombolysis and in 20.8% of the ones 
treated by systemic thrombolysis, without statistical significance. Moreover, the proportion of 
minor bleeding was comparable in the two groups of patients. There was no intracranial bleed-
ing. Disseminated intravascular coagulation occurred in 1 patient with systemic thrombolysis.
Conclusions: The rate of clinical success and the regression of RV overload were significantly 
higher in patients treated by pulmonary intra-arterial thrombolysis. The results regarding the 
efficiency of the pulmonary intra-arterial thrombolysis in high-risk PE are encouraging, the 
mortality in these patients being significantly lower than the one for systemic administration 
of the thrombolytic agent. (Cardiol J 2015; 22, 4: 467–474)
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Introduction
High-risk pulmonary embolism (PE) repre-
sents an important health problem in emergency 
cardiology, being associated with a high rate of 
mortality [1].
If the early mortality after PE with a high 
risk is due to arterial hypotension, afterwards, the 
major cause of death is represented by acute right 
cardiac failure, the mortality after 3 months being 
approximately 50% [1–3]. In the International 
Cooperative Pulmonary Embolism Registry, the 
90-day mortality rate for patients with acute PE and 
systolic blood pressure < 90 mm Hg was 52.4% 
[4, 5]. In the Germany-based Management Strategy 
and Prognosis of Pulmonary Embolism Registry, 
in-hospital mortality was 25% for those presenting 
with cardiogenic shock [4, 6].
Survival in high risk PE depends on the suc-
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tion. Studies demonstrated that patients receiving 
thrombolytic therapy had more rapid resolution of 
angiographic obstruction and hemodynamic distur-
bances than those receiving heparin alone [7–9].
In 1997, the Food and Drug Administration 
approved the use of thrombolytic therapy for PE 
associated with hypotension and significant hy-
poxemia despite oxygen supplementation [7, 10]. 
One of the actual controversies of the thrombolytic 
therapy for PE is which thrombolytic agent is the 
most effective and should the agent be adminis-
tered systemically or locally? Many studies dem-
onstrated that streptokinase (SK), urokinase and 
recombinant tissue plasminogen activator have 
equal safety profiles and efficacy in angiographic 
resolution of clot and improvement of hemody-
namic disturbances [7, 11].
An alternative to systemic thrombolysis is rep-
resented by pulmonary intra-arterial thrombolysis, 
however there is still a continuous controversy 
regarding superior benefits yet with lower risk of 
bleeding. There are few situations that suggest 
a superior efficiency of pulmonary intra-arterial 
thrombolysis in high risk PE and the thrombolytic 
agents that are used are the following: tissue plas-
minogen activator, monoteplase, urokinase [2].
In our study, we used SK as thrombolytic agent 
administrated systemic in one group of patients and 
pulmonary intra-arterial in the other group. The 
results regarding the efficiency of the pulmonary 
intra-arterial thrombolysis in PE with high risk are 
encouraging, the mortality in these patients being 
significantly lower than systemic administration of 
the thrombolytic agent.
The aim of this study is to assess the efficacy 
and safety of pulmonary intra-arterial thrombolysis 
with SK compared with systemic thrombolysis.
Methods
Study population
The patients admitted to the study have ac-
complished the following criteria of inclusion: 
(1) Diagnosis of high risk PE; (2) Informed consent 
of the patient regarding the treatment.
Study protocol
Exclusion criteria were represented by: hemor-
rhagic stroke or stroke of another unknown etiology 
somewhere in the past, ischemic stroke in the last 
6 months, lesions or cancer of the central nervous 
system, major trauma, surgery or recent cranial 
trauma (the last 3 weeks), gastrointestinal bleeding 
in the last month, known bleeding, and pregnancy.
All the echocardiographic and angiographic 
studies have been performed in the same labora-
tories using the same contrast agent and the same 
protocol of diagnosis.
The modality of giving the thrombolytic agent, 
systemic or intrapulmonary, was randomly chosen. 
The thrombolytic agent was: SK 250,000 UI/30 min 
followed by 100,000 UI/h. The adjuvant therapy 
was: anticoagulants (unfractionated heparin, low-
molecular-weight heparin), antiplatelet agents 
(clopidogrel, aspirin) and their associations.
The followed parameters, at the admission 
in the intensive care unit and at the end of the 
treatment, have been grouped as follows: clinical 
features, hemodynamic parameters, electrocardio-
graphic and angiographic aspects. Clinical evolution 
was evaluated by the presence of dyspnea, chest 
pain, syncope and asymptomatic status at the end 
of the treatment. Hemodynamic parameters were: 
systolic arterial blood pressure less than 90 mm Hg, 
peripheral oxygen saturation and heart rate. The 
electrocardiographic study was constant in the fol-
lowed evolution of the axis of QRS complex (A QRS), 
reversibility of right bundle block, S1Q3T3 aspect, 
negative T waves from V1 up to V3 and the atrial 
arrhythmias. The followed echocardiographic pa-
rameters were: telediastolic diameter of right 
ventricular (RVD2), lateromedial diameter of right 
atrium (RA minor-axis), pressure gradient between 
right ventricle (RV) and right atrium (RA) (PRV-RA), 
right bundle’s diameter of the right pulmonary 
artery (RPA) and the inferior cave vein’s diameter 
(IVC). The evolution of the mean pressure in the 
pulmonary artery (mean PAP) was monitored an-
giographically. The valid patients were represented 
by those who had their parameters valid before and 
after the thrombolysis was performed.
The efficiency and safety profile of the used 
treatment has been evaluated by monitoring the 
complete thrombolysis (evaluated angiographic 
and/or echocardiographic), the appearance of major 
bleeding complications (brain bleeding or gastro-
intestinal, massive hematoma on the puncture 
site or acute post-hemorrhagic anemia) or minor 
complications (minor bleeding, hematoma on the 
puncture site, transient ischemic attack) and dis-
seminated intravascular coagulation (CID).
Statistical analysis
The centralization of the data was done nomi-
nally and numerically. Nominal data was character-
ized by absolute and relative frequency. Numerical 
data have been studied from the view of the param-
eters of the central tendency (media and median) 
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and the dispersion (standard deviation, minimum, 
maximum, rank, quartiles).
Intergroup statistical data were analyzed 
through the nominal variables using Fisher’s exact 
test. In the case of numeric variables, the distribu-
tion of data was determined by using Shapiro-Wilk’s 
test. The not normal distribution of data imposed 
the use of nonparametric Mann-Whitney U test. 
The level of statistical significance was 0.05 for all 
tests that have been used.
Statistical analysis of the data was performed 
with SPSS Statistics version 17.
Results
Fifty-two consecutive patients included in the 
study were randomized in two groups of treatment: 
the administration of SK directly in the pulmonary 
artery (in situ) in 28 patients and systemic (in-
travenous) in 24 patients. The characteristics of 
the patients at the initial moment of the study are 
presented in Table 1.
Clinical results
At the end of the study, 27 (96.4%) patients 
with in situ thrombolysis were asymptomatic, 
compared with 17 (70.8%) patients with systemic 
thrombolysis. Statistical analysis showed a signifi-
cant statistical difference between the two groups 
(p = 0.018; exact sig [2-sided]).
Hemodynamic findings
The evaluation of hemodynamic parameters, 
before and after thrombolysis, confirmed a dif-
ferent evolution in the two groups. Cardiogenic 
shock initially identified in 18 patients, the same 
in both groups, has totally remitted in the group 
with thrombolysis in situ, meanwhile, in the group 
with systemic thrombolysis, it still remained in 
7 (29.2%) patients (p < 0.03). The improvement 
of SO2 was registered in both groups, without sig-
nificant statistical differences (p < 0.017). Heart 
rate has dropped in both groups, in thrombolysis 
in situ from a median of 100 bpm to 70 bpm (32%) 
and in systemic thrombolysis from a median of 100 
bpm to 75 bpm (15.5%), with registered significant 
statistical difference.
Electrocardiographic results
Regarding transient right bundle branch block, 
S1Q3T3, negative T wave in V1–V3, and atrial ar-
rhythmias there were no significant differences 
between groups.
Echocardiographic results
The results of echocardiographic examination 
are summarized in Table 2. RVD2, in thrombolysis 
in situ reduced from a maximum of 52 mm (range 
22 mm) to a maximum of 41 mm (range 14 mm), 
median decreased only with 7%, presenting a sig-
nificant statistical difference (p = 0.036; exact sig. 
1-tailed). In systemic thrombolysis, 7 patients (de-
ceased, from whom 3 with bleeding complication) 
did not present improvement of RVD2, compared 
to thrombolysis in situ, where only in 2 patients 
the RVD2 did not decrease (Fig. 1).
RA minor-axis was reduced in both types of 
thrombolysis. Secondary to the in situ administra-
tion, RA minor-axis dropped from a maximum of 
57 mm (range 24 mm) to a maximum of 48 mm 
(range 24 mm), median decreasing by 14%. In sys-
temic administration, RA minor-axis dropped from 
a maximum of 67 mm (range 32 mm) to a maximum 
of 66 mm (range of 36 mm), median decreasing 
by only 3%, representing a significant statistical 
difference (p = 0.009; exact sig. 1-tailed). The 
Table 1. Selected baseline characteristics of  
patients.
Route of thrombolytic  
administration
In situ Systemic 
vein




Age [year] 56.3 ± 13.2 532 ± 13
Time to thrombolysis, 
median [day]
2.5 3
Predisposing factors for VTE:
Chronic heart failure 8 (28.6%) 4 (16.4%)
Oral contraceptive 
therapy
4 (14.3%) 1 (4.2%)
Malignancy 2 (7.1%) 2 (8.3%)
Previous VTE 8 (28.6%) 14 (53.8%)
Bed rest > 3 days 4 (14.3%) 4 (16.7%)
Obesity 17 (60.7%) 15 (62.5%)
Varicose veins 14 (50%) 10 (41.7%)
Clinical markers:
Dyspnea 28 (100%) 24 (100%)
Chest pain 18 (63.4%) 14 (53.8%)
Syncope 11 (39.3%) 9 (37.5%)
VTE — venous thromboembolism
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lack of regression of RA minor-axis was recorded 
on 8 patients with systemic thrombolysis, from 
whom 7 deceased (1 major bleeding complication 
and 3 with minor bleeding) and on 3 patients with 
thrombolysis in situ with minor bleeding complica-
tion (Fig. 1).
PRV-RA had different variation in the two modali-
ties of administration of the thrombolytic agent. 
In the case of thrombolysis in situ, the maximum 
dropped from 80 mm Hg (range 75 mm Hg) to 
70 mm Hg (range 60 mm Hg), compared with systemic 
thrombolysis where the maximum remained 
100 mm Hg, but the range increased from 75 mm Hg 
before thrombolysis to 85 mm Hg at the end of the 
treatment. The analysis of percentage reduction of 
PRV-RA, depending on the modality of administration 
of thrombolytic agent, showed a reduction by 43.5% 
in thrombolysis in situ and by 35% in systemic 
thrombolysis, showing a significant statistical dif-
ference (p = 0.036; exact sig. 1-tailed). Maintaining 
the same value of PRV-RA, it was registered only in 
the group with systemic thrombolysis in 6 patients 
(deceased patients, from whom 1 with major bleed-
ing and 3 with minor bleeding) (Fig. 2).
Decreasing of IVC diameter was registered 
both in the case of thrombolysis in situ as well as 
in systemic thrombolysis. In situ administration 
determined a reduction of IVC from a maximum 
of 30 mm (range 18 mm) to a maximum of 25 mm 
(range 11 mm), compared with systemic adminis-
tration in which IVC decreased from a maximum 
of 33 mm (range 18 mm) to a maximum of 28 mm 
(range 13 mm). Median IVC presented a reduction 
of 25% in thrombolysis in situ and a reduction of 
4% in systemic thrombolysis, showing a significant 
statistical difference (p = 0.002; exact sig. 1-tailed). 
IVC remained the same in 9 patients in systemic 
thrombolysis group (7 deceased — out of whom 
1 patient with massive bleeding and 3 with minor 
bleeding, and 2 surviving patients) and in 3 patients 
in the group with thrombolysis in situ (all 3 with 
minor bleeding) (Fig. 2).
The evaluation of RPA diameter before and 
after thrombolysis showed significant differences 
depending on the modality of the administration 
of the thrombolytic (p = 0.027; exact sig. 1-tailed) 
median RPA diameter in systemic thrombolysis 
having approximately the same value, compared 
with thrombolysis in situ in which decreased by 
14%. In thrombolysis in situ, RPA decreased from 
a maximum of 35 mm (range 13 mm) to a maximum 
of 32 mm (range 13 mm), compared to systemic 
thrombolysis in which RPA decreased from a maxi-
mum of 33 mm (range 11 mm) to a maximum of 
30 mm (range 11 mm). RPA remained the same in 
7 patients from the group with systemic throm-
bolysis (patients deceased, out of which 1 patient 
with massive bleeding and 3 with minor bleeding) 
and 1 patient in the group with thrombolysis in 
situ (Fig. 3).
The qualitative evaluation of the RV func-
tion was done by monitoring the reversibility of 
paradoxical movement of interventricular sept 
and the hypokinesia of the free wall of RV. In the 
group with thrombolysis in situ, from 26 patients 
with paradoxical movement of interventricular sept 
before the thrombolysis was made, the paradoxical 
movement was transitory, in 13 (50%) patients and 
the hypokinesia of the free wall of RV, present at the 
beginning in 7 patients, was transitory in 5 of them 
(71.4%). In the group with systemic thrombolysis, 
out of 22 patients with paradoxical movement 
of interventricular sept before the thrombolysis 
Table 2. Echocardiographic parameters.
Route of thrombolytic  
administration
In situ Systemic vein
RVD2 (median):
Before [mm] 42 43
After [mm] 32 36
PD [%] 22A 7A
RA minor-axis (median):
Before [mm] 47 46
After [mm] 40 45
PD [%] 14B 3B
PRV-RA (median):
Before [mm Hg] 48 49
After [mm Hg] 26 32
PD [%] 43.5C 35C
IVC (median):
Before [mm] 21.5 24
After [mm] 17 20.5
PD [%] 25D 4D
RPA (median):
Before [mm] 27.5 27
After [mm] 25 27.5
PD [%] 14E 0E
Ap = 0.036; Bp = 0.009; Cp = 0.038; Dp = 0.002; Ep = 0.027: signifi-
cance of difference between the two groups after the thrombolysis 
(exact sig. [1-tailed]); PD — percentage difference; RVD2 — teledi-
astolic diameter of right ventricular; RA minor-axis — lateromedial 
diameter of right atrium; PRV-RA — pressure gradient between right 
ventricle and right atrium; IVC — inferior cave vein’s diameter;  
RPA — right bundle’s diameter of the right pulmonary artery
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was made, in 15 (68.2%) it was transitory, and 
the hypokinesia of the free wall of RV, present 
at the beginning in 4 patients, was transitory in 
2 (50%) patients. The difference recorded in the 
two modalities of thrombolysis was not statistically 
significant neither in the case of paradoxical move-
ment of interventricular sept (p = 0.249; exact sig. 
2-sided) nor in the case of hypokinesia of free wall 
of RV (p = 0.576; exact sig. 2-sided).
Angiographic finding
The evolution of mean PAP was dependent 
on the mode of administration of the thrombo-
lytic agent. In thrombolysis in situ, the mean PAP 
reduced from a maximum of 66 mm Hg (range 
42 mm Hg) to a maximum of 45 mm Hg (range 
35 mm Hg), the median reducing by 43%. Secondary 
to systemic administration of thrombolytic agent, 
the maximal value of the mean PAP remained 
the same (52 mm Hg, range 36 mm Hg), with the 
median reducing insignificantly from 50 mm Hg to 
48 mm Hg (p < 0.001; exact sig. 1-tailed) (Fig. 4).
Total lysis of the thromb (evaluated angio-
graphic and/or echocardiographic) was objectified 
in 12 (50%) out of 24 patients evaluated from the 
group with thrombolysis in situ. In the patients 
with systemic thrombolysis, the lysis of the entire 
thromb was objectified in 5 of them (41.7%) from 
a total of 12 patients evaluated. Statistical analysis 
didn’t show greater efficiency in thrombolysis in 
situ (p = 0.454; exact sig. 1-sided).
Safety profile
The thrombolytic agent that had been used 
was SK. The median of the treatment was 3 days, 
with limits between 1 and 4 days in thrombolysis in 
Figure 1. Individual data and percentage difference for telediastolic diameter of right ventricular (RVD2) and laterome-
dial diameter of right atrium (RA minor-axis) before and after thrombolysis. Individual data are ordered ascendently. 
Box plots express median, 25% and 75% quartiles, minimum and maximum.
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situ, and 2 days, with limits between 1 and 3 days, 
in systemic thrombolysis. The statistical analysis 
of the duration of the thrombolytic treatment 
depending on the modality of the administration, 
showed the fact that the duration of the throm-
bolysis in situ was significantly longer compared 
with the systemic thrombolysis (p = 0.002; exact 
sig. 1-tailed).
The safety of the thrombolytic treatment was 
evaluated by analyzing the occurrence of compli-
cations. Major bleeding complications occurred in 
4 (14.3%) patients in the group with thrombolysis 
in situ, compared to 5 (20.8%) patients in the 
group with systemic thrombolysis, minor bleeding 
being present in 6 (21.4%) patients in the group 
with thrombolysis in situ, compared to 7 (29.2%) 
Figure 2. Individual data and percentage difference for pressure gradient between right ventricle and right atrium 
(PRV-RA) and inferior cave vein’s diameter (IVC) before and after thrombolysis. Individual data are ordered ascendently. 
Box plots express median, 25% and 75% quartiles, minimum and maximum.
patients in the group with systemic thrombolysis. 
CID appeared in 1 (3.6%) patient with systemic 
thrombolysis. By analyzing the significant dif-
ference of the two ways of administration of the 
thrombolytic, the bleeding complications wasn’t 
significantly more frequent in systemic thromboly-
sis (major bleeding, p = 0.270; exact sig. 1-sided; 
minor bleeding, p = 0.373; exact sig. 1-sided).
Mortality
Of the total number of the patients included 
in this study, 7 were registered as deceased, all of 
them from the group with systemic thrombolysis 
(29.2%), the mortality being significantly higher in 
the patients with systemic thrombolysis (p = 0.003; 
exact sig. 1-sided).
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Figure 4. Individual data and percentage difference for 
mean pressure in the pulmonary artery (mean PAP) be-
fore and after thrombolysis. Individual data are ordered 
ascendently. Box plots express median, 25% and 75% 
quartiles, minimum and maximum.
Figure 3. Individual data and percentage difference for 
right bundle’s diameter of the right pulmonary artery 
(RPA) before and after thrombolysis. Individual data are 
ordered ascendently. Box plots express median, 25% 
and 75% quartiles, minimum and maximum.
Discussion
Because the patients with massive PE are at 
high risk of death, the American College of Chest 
Physicians and the European Society of Cardiology 
have recommended thrombolytic therapy for these 
patients [2].
The actual controversies are related in the 
first place to the method of administration of the 
thrombolytic agent. Thus, some of the authors do 
not report differences in efficiency between lo-
cal and systemic administration, several reports 
showed that local thrombolysis improves severe 
hemodynamic impairment rapidly and more safety 
[12, 13].
In our study, 28 patients with acute high risk 
PE were treated by intra-arterial thrombolysis, 
with a clinical success rate of 96.4%, the results 
being superior to the previous review [2, 13]. The 
rate of clinical success in patients with systemic 
thrombolysis was significantly lower (70.8%). Re-
gression of RV overload after local thrombolysis 
in PE is associated with reduced morbidity and 
mortality [14]. In our study, PRV-RA has decreased 
significantly more in patients treated by pulmonary 
intra-arterial thrombolysis instead of systemic 
thrombolysis.
Reported complications associated with local 
thrombolysis include RV perforation, significant 
bleeding at the puncture site, mechanical hemoly-
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sis and blood loss [2, 15–17]. Among 304 patients 
from the International Cooperative Pulmonary 
Embolism Registry (ICOPER) who received PE 
thrombolysis, 21.7% suffered major bleeding and 
3%had intracranial bleeding [18].
Major bleeding complications appeared in our 
study in 14.3% of the patients with high risk PE 
with in situ thrombolysis and in 20.8% of the ones 
treated by systemic thrombolysis, but without 
statistical significance. There was no intracranial 
bleeding present in our study.
Also, the proportion of minor bleeding was 
comparable in the two groups of patients. Dis-
seminated intravascular coagulation occurred in 
1 patient with systemic thrombolysis.
The most impressive result was the one re-
garding the mortality during the hospitalization, 
which was 0% in the group with local thrombolysis 
with SK and 29.2% in the group with systemic 
thrombolysis, with a significant statistical differ-
ence. The surviving of all the patients with PE 
with high risk who had pulmonary intra-arterial 
thrombolysis was remarkable, the results being 
superior to the ones registered in previous situa-
tions [2, 18].
The present study possesses some limitations 
regarding non-randomized study, that is relatively 
small samples.
Conclusions
Local thrombolysis in high risk PE improves 
severe hemodynamic impairment rapidly and safe-
ty. In situ thrombolysis has a significantly higher 
rate of clinical success, which reduces morbidity 
and mortality.
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